• Empower your research with Pharmidex, a leading CRO offering advanced solutions in Bioanalysis (GLP/GCP), CNS, DMPK, Oncology, Immunology, Respiratory, and Toxicology (GLP).

    Slide title

    Empower your research with Pharmidex, a leading CRO offering advanced solutions in Bioanalysis (GLP/GCP), CNS, DMPK, Oncology, Immunology, Respiratory, and Toxicology (GLP).

    Button
  • Unlock the full potential of your research with Pharmidex, your trusted partner in drug discovery, offering unparalleled expertise and innovative solutions to drive your projects toward success.

    Slide title

    Unlock the full potential of your research with Pharmidex, your trusted partner in drug discovery, offering unparalleled expertise and innovative solutions to drive your projects toward success.

    Button

Service Offerings

ADMET (IN VITRO)
BIOANALYSIS (GLP/GCP, Discovery)
Clinical Pathology
Biomarker
DMPK (IN VIVO)
Histology
IN SILICO DRUG DISCOVERY
TOXICOLOGY (NON-GLP/GLP)

Therapeutic Areas

Services By Developmental Phase

Latest News

Who We Are

About us

Pharmidex is a contract research organisation (CRO) that provides translational solutions using its world-renowned expertise in CNS, oncology, respiratory, DMPK, drug discovery and ADMET/pharmacokinetics.


Founded in the UK, in 2002, Pharmidex operates in state-of-the-art facilities in Hertfordshire to provide high-quality experimental data and expert guidance to support drug discovery and development.

Home

Key Facts

Experts in therapeutic preclinical models 


Accredited by AAALAC and the MHRA to perform GLP and GCP certified services

Home

Services

Single site service offering with 15,000+ studies conducted to date


Quick turnaround times, cost effective research, expert interpretation and customer-focused approach

Home

Our History

Successfully helped multiple clients reach clinical development since 2002

News

DMPK Services News! More News!

🚀 Pharmidex at the R&D Society Life Science Workshop!

June 11, 2025
Pharmidex team are delighted to participate in workshop on "Re-shaping UK life science commercialisation strategy" organised by The Research and Development Society on Wednesday 11th June, at Mereside, Alderley Park. If you are attending, please linkup with our colleague Mo Alavijeh who will be delighted to meet you. Jamie Phadke , Alderley Park #UKlifescience https://lnkd.in/e6uKsRcN

🔬 Pharmidex at the 4th RSC Anglo-Nordic Medicinal Chemistry Symposium

June 10, 2025
Martin Barrett , Head of Business Development, will attend the symposium on 10–13 June 2025 at Hotel Comwell Borupgaard, Denmark. The event gathers top European scientists to discuss drug discovery. Martin looks forward to connecting with academia, CROs, and pharma to explore collaborations and showcase Pharmidex’s services from in silico to in vivo pharmacology. Attending? Let’s connect! 🔗 https://lnkd.in/ev7TW7WG

🔬 Pharmidex is proud to contribute to new research!

June 10, 2025
We’re excited to announce our involvement in the recent publication: "Anti-Inflammatory Activity of Ensifentrine: A Novel, Selective Dual Inhibitor of PDE3 and PDE4" 📄 https://pubmed.ncbi.nlm.nih.gov/40245851/ 📄 https://www.pharmidex.com/publications-by-pharmidex Dr. Radhakrishnan Venkatasamy , our Senior Scientist in autoinflammatory and immune diseases, co-authored this study highlighting Ensifentrine’s anti-inflammatory potential. This reflects Pharmidex’s commitment to advancing therapies through expert science and collaboration.
Services by Department